Skip to main content

Articles

Page 4 of 61

  1. Migraine is a neurological disorder characterized by intense, debilitating headaches, often coupled with nausea, vomiting and sensitivity to light and sound. Whilst changes in sensory processes during a migrai...

    Authors: Noemi Meylakh and Luke A. Henderson
    Citation: The Journal of Headache and Pain 2022 23:5
  2. Migraine is a common brain disorder that predominantly affects women. Migraine pain seems mediated by the activation of mechanosensitive channels in meningeal afferents. Given the role of transient receptor po...

    Authors: G. Krivoshein, E. A. Tolner, AMJM van den Maagdenberg and R. A. Giniatullin
    Citation: The Journal of Headache and Pain 2022 23:4

    The Correction to this article has been published in The Journal of Headache and Pain 2022 23:17

  3. Several inflammatory and vascular molecules, and neurotrophins have been suggested to have a possible role in the development of migraine. However, pathophysiological events leading to migraine onset and trans...

    Authors: Mohammad Mozafarihashjin, Mansoureh Togha, Zeinab Ghorbani, Abolfazl Farbod, Pegah Rafiee and Fahimeh Martami
    Citation: The Journal of Headache and Pain 2022 23:3
  4. Neurological symptoms are frequent among patients with COVID-19. Little is known regarding the repercussions of neurological symptoms for patients and how these symptoms are related to one another.

    Authors: Pedro Augusto Sampaio Rocha-Filho, Pedro Mota Albuquerque, Larissa Clementino Leite Sá Carvalho, Mylana Dandara Pereira Gama and João Eudes Magalhães
    Citation: The Journal of Headache and Pain 2022 23:2
  5. Chronic migraine places a disabling burden on patients, which is extensively modeled by the nitroglycerin (NTG)-treated animal model. Although the NF-κB pathway is involved in an increase in CGRP levels and ac...

    Authors: Hao Chen, Xueqian Tang, Jin Li, Bangyan Hu, Wenqin Yang, Meng Zhan, Tengyun Ma and Shijun Xu
    Citation: The Journal of Headache and Pain 2022 23:1
  6. Migraine preventive treatment with CGRP(−receptor) monoclonal antibodies (mAbs) has a positive effect on patients’ health-related quality of life (HRQoL). The German treatment guidelines recommend discontinuin...

    Authors: Maria Terhart, Jasper Mecklenburg, Lars Neeb, Lucas Hendrik Overeem, Anke Siebert, Maureen Steinicke, Bianca Raffaelli and Uwe Reuter
    Citation: The Journal of Headache and Pain 2021 22:158
  7. Fremanezumab, a fully humanized monoclonal antibody (IgG2Δa) that selectively targets calcitonin gene-related peptide (CGRP), is approved for migraine prevention in adults. Real-world data on the effectiveness...

    Authors: Peter McAllister, Lois Lamerato, Lynda J. Krasenbaum, Joshua M. Cohen, Krishna Tangirala, Stephen Thompson, Maurice Driessen, Julian Casciano, Zenobia Dotiwala and Alexander Mauskop
    Citation: The Journal of Headache and Pain 2021 22:156
  8. The purpose of this narrative review is to examine the literature investigating a causal relationship between stress and migraine and evaluate its implications for managing migraine.

    Authors: Anker Stubberud, Dawn C. Buse, Espen Saxhaug Kristoffersen, Mattias Linde and Erling Tronvik
    Citation: The Journal of Headache and Pain 2021 22:155
  9. Monoclonal antibodies anti-calcitonin gene-related peptide (mAbs anti-CGRP) pathway are effective and safe on migraine prevention. However, some drug agencies limited these treatments to one year due to their ...

    Authors: Fabrizio Vernieri, Nicoletta Brunelli, Roberta Messina, Carmelina Maria Costa, Bruno Colombo, Paola Torelli, Simone Quintana, Sabina Cevoli, Valentina Favoni, Florindo d’Onofrio, Gabriella Egeo, Renata Rao, Massimo Filippi, Piero Barbanti and Claudia Altamura
    Citation: The Journal of Headache and Pain 2021 22:154
  10. Headache disorders are disabling, with major consequences for productivity, yet the literature is silent on the relationship between headache-attributed disability and lost productivity, often erroneously rega...

    Authors: Hallie Thomas, Simple Futarmal Kothari, Andreas Husøy, Rigmor Højland Jensen, Zaza Katsarava, Michela Tinelli and Timothy J. Steiner
    Citation: The Journal of Headache and Pain 2021 22:153
  11. Migraine prevalence is age and sex dependent, predominating in women in early and middle adulthood; however, migraine also represents a substantial burden for men and adults of all ages. Thus, understanding th...

    Authors: Antoinette MaassenVanDenBrink, Gisela M. Terwindt, Joshua M. Cohen, Steve Barash, Verena Ramirez Campos, Maja Galic, Xiaoping Ning and Mikko Kärppä
    Citation: The Journal of Headache and Pain 2021 22:152
  12. Patient-Reported Outcomes (PROs) have been developed to numerically quantify disability, impact and quality of life. They have been widely used in migraine clinical trials. However, we still do not know which ...

    Authors: Alicia Alpuente, Victor J Gallardo, Edoardo Caronna, Marta Torres-Ferrus and Patricia Pozo-Rosich
    Citation: The Journal of Headache and Pain 2021 22:151
  13. An imbalance between inhibitory and excitatory neurometabolites has been implicated in chronic pain. Prior work identified elevated levels of Gamma-aminobutyric acid + macromolecules (“GABA+”) using magnetic r...

    Authors: Aimie L. Peek, Andrew M. Leaver, Sheryl Foster, Nicolaas A. Puts, Georg Oeltzschner, Luke Henderson, Graham Galloway, Karl Ng, Kathryn Refshauge and Trudy Rebbeck
    Citation: The Journal of Headache and Pain 2021 22:150
  14. Calcitonin gene-related peptide ligand/receptor (CGRP) antibodies effectively reduce headache frequency in migraine. It is understood that they act peripherally, which raises the question whether treatment mer...

    Authors: Anne Thiele, Lara Klehr, Sebastian Strauß, Anselm Angermaier, Ulf Schminke, Martin Kronenbuerger, Steffen Naegel and Robert Fleischmann
    Citation: The Journal of Headache and Pain 2021 22:149
  15. Patients with visual snow syndrome (VSS) suffer from a debilitating continuous (“TV noise-like”) visual disturbance. They report problems with vision at night and palinopsia despite normal visual acuity. The u...

    Authors: Ozan E. Eren, Andreas Straube, Florian Schöberl, Ruth Ruscheweyh, Thomas Eggert and Christoph J. Schankin
    Citation: The Journal of Headache and Pain 2021 22:148
  16. Accumulating studies have indicated a wide range of brain alterations with respect to the structure and function of classic trigeminal neuralgia (CTN). Given the dynamic nature of pain experience, the explorat...

    Authors: Pengfei Zhang, Yanli Jiang, Guangyao Liu, Jiao Han, Jun Wang, Laiyang Ma, Wanjun Hu and Jing Zhang
    Citation: The Journal of Headache and Pain 2021 22:147
  17. Purinergic P2X7 receptor plays an important role in migraine pathophysiology. Yet precise molecular mechanism underlying P2X7R signaling in migraine remains unclear. This study explores the hypothesis that P2X...

    Authors: Lingdi Nie, Dongqing Ma, John P. Quinn and Minyan Wang
    Citation: The Journal of Headache and Pain 2021 22:146
  18. Migraine represents one of the most prevalent neurological conditions worldwide. It is a disabling condition with high impact on the working situation of migraineurs. Interestingly, gender-related differences ...

    Authors: Oreste Affatato, Maud Miguet, Helgi B. Schiöth and Jessica Mwinyi
    Citation: The Journal of Headache and Pain 2021 22:145
  19. Transcranial direct current stimulation (tDCS) could counteract the pathophysiological triggers of migraine attacks by modulating cortical excitability. Several pilot randomized controlled trials (RCTs) assess...

    Authors: Raffaele Ornello, Valeria Caponnetto, Susanna Ratti, Giulia D’Aurizio, Chiara Rosignoli, Francesca Pistoia, Michele Ferrara, Simona Sacco and Aurora D’Atri
    Citation: The Journal of Headache and Pain 2021 22:144
  20. Patients with migraine have an increased relative risk of cardio- and cerebrovascular events, and some migraine treatments may exacerbate this risk. The primary objective of this analysis was to determine whet...

    Authors: Timothy R. Smith, Egilius L. H. Spierings, Roger Cady, Joe Hirman, Anders Ettrup and Vivienne Shen
    Citation: The Journal of Headache and Pain 2021 22:143
  21. Migraine is a common brain disorder but reliable diagnostic biomarkers in blood are still lacking. Our aim was to identify, using proton nuclear magnetic resonance (1H-NMR) spectroscopy, metabolites in serum that...

    Authors: Aster V. E. Harder, Lisanne S. Vijfhuizen, Peter Henneman, Ko Willems van Dijk, Cornelia M. van Duijn, Gisela M. Terwindt and Arn M. J. M. van den Maagdenberg
    Citation: The Journal of Headache and Pain 2021 22:142
  22. Although migraine is less common in older people, preventive treatment of migraine in these individuals may be more challenging due to the presence of multiple comorbidities and polypharmacy. Additionally, evi...

    Authors: Stephanie J. Nahas, Steffen Naegel, Joshua M. Cohen, Xiaoping Ning, Lindsay Janka, Verena Ramirez Campos, Lynda J. Krasenbaum, Dagny Holle-Lee, David Kudrow and Christian Lampl
    Citation: The Journal of Headache and Pain 2021 22:141

    The Correction to this article has been published in The Journal of Headache and Pain 2022 23:57

  23. Health care costs of migraine constitute a major issue in health economics. Several publications analyzed health care costs for adult migraine patients, based on questionnaires or secondary (health insurance) ...

    Authors: Viola Obermeier, Monika Murawski, Florian Heinen, Mirjam N. Landgraf, Andreas Straube, Rüdiger von Kries and Ruth Ruscheweyh
    Citation: The Journal of Headache and Pain 2021 22:140
  24. Occipital transcranial direct current stimulation (tDCS) is an effective and safe treatment for migraine attack prevention. Structural brain alterations have been found in migraineurs in regions related to pai...

    Authors: Simon Schading, Heiko Pohl, Andreas Gantenbein, Roger Luechinger, Peter Sandor, Franz Riederer, Patrick Freund and Lars Michels
    Citation: The Journal of Headache and Pain 2021 22:139
  25. Pain is generally concomitant with an inflammatory reaction at the site where the nociceptive fibers are activated. Rodent studies suggest that a sterile meningeal inflammatory signaling cascade may play a rol...

    Authors: Şefik Evren Erdener, Zeynep Kaya and Turgay Dalkara
    Citation: The Journal of Headache and Pain 2021 22:138
  26. Post-traumatic headache (PTH) is a very common symptom following mild traumatic brain injury (mTBI), yet much remains unknown about the underlying pathophysiological mechanisms of PTH. Neuroimaging studies sug...

    Authors: Fengfang Li, Liyan Lu, Song’an Shang, Huiyou Chen, Peng Wang, Vijaya Prakash Muthaiah, Xindao Yin and Yu-Chen Chen
    Citation: The Journal of Headache and Pain 2021 22:137
  27. General practitioners (GPs) diagnose and manage a majority of headache patients seeking health care. With the aim to understand the potential for clinical improvement and educational needs, we performed a stud...

    Authors: Espen Saxhaug Kristoffersen, Kashif Waqar Faiz, Jakob Møller Hansen, Erling Andreas Tronvik, Jan C. Frich, Christofer Lundqvist and Bendik Slagsvold Winsvold
    Citation: The Journal of Headache and Pain 2021 22:136
  28. Headache affects 90–99% of the population. Based on the question “Do you think that you never ever in your whole life have had a headache?” 4% of the population say that they have never experienced a headache....

    Authors: Isa Amalie Olofsson, Jeppe Hvedstrup, Katrine Falkenberg, Mona Ameri Chalmer, Henrik Winther Schytz, Miguel Benjamin Pedersen, Henrik Ullum, Ole Birger Pedersen, Jes Olesen and Thomas Folkmann Hansen
    Citation: The Journal of Headache and Pain 2021 22:134
  29. Erenumab, the first-in-class fully human monoclonal antibody targeting the calcitonin gene-related peptide receptor, was shown to be efficacious and safe for the prophylactic treatment of migraine in adults in...

    Authors: Andreas Straube, Philipp Stude, Charly Gaul, Katrin Schuh and Mirja Koch
    Citation: The Journal of Headache and Pain 2021 22:133
  30. Lasmiditan (LTN) is a selective 5-HT1F receptor agonist for the acute treatment of migraine in adults. We present detailed safety findings from the placebo-controlled, double-blind Phase 3 study, of LTN treatment...

    Authors: C Tassorelli, S Bragg, JH Krege, EG Doty, PA Ardayfio, D Ruff, SA Dowsett and T Schwedt
    Citation: The Journal of Headache and Pain 2021 22:132
  31. Authors: Sara Bottiroli, Roberto De Icco, Gloria Vaghi, Stefania Pazzi, Elena Guaschino, Marta Allena, Natascia Ghiotto, Daniele Martinelli, Cristina Tassorelli and Grazia Sances
    Citation: The Journal of Headache and Pain 2021 22:131

    The original article was published in The Journal of Headache and Pain 2021 22:114

  32. In this study, we aimed to investigate the spontaneous neural activity in the conventional frequency band (0.01−0.08 Hz) and two sub-frequency bands (slow-4: 0.027–0.073 Hz, and slow-5: 0.01–0.027 Hz) in tensi...

    Authors: Shuxian Zhang, Huayun Li, Qinyan Xu, Chao Wang, Xue Li, Jiawei Sun, Yaqi Wang, Tong Sun, Qianqian Wang, Chengcheng Zhang, Jili Wang, Xize Jia and Xihe Sun
    Citation: The Journal of Headache and Pain 2021 22:129
  33. Several drugs are available for the preventive treatment of both episodic and chronic migraine. The choice of which therapy to initiate first, second, or third is not straightforward and is based on multiple f...

    Authors: Fenne Vandervorst, Laura Van Deun, Annelies Van Dycke, Koen Paemeleire, Uwe Reuter, Jean Schoenen and Jan Versijpt
    Citation: The Journal of Headache and Pain 2021 22:128
  34. Migraine sufferers face difficulties getting appropriate care and treatment. Migraine is associated with reduced gray matter volume (GMV) in several brain regions, which could be related to various clinical ch...

    Authors: Shana A.B. Burrowes, Olga Goloubeva, Michael L Keaser, Jennifer A. Haythornthwaite and David A. Seminowicz
    Citation: The Journal of Headache and Pain 2021 22:127
  35. The MIDAS is the most used questionnaire to evaluate migraine-related disability, but its utility to assess treatment response remains unclear. Our aim was to estimate the MIDAS’ minimal important change (MIC)...

    Authors: Gabriela F. Carvalho, Kerstin Luedtke and Tobias Braun
    Citation: The Journal of Headache and Pain 2021 22:126
  36. To compare symptoms of clinical androgen deficiency between men with migraine, men with cluster headache and non-headache male controls.

    Authors: Iris E. Verhagen, Roemer B. Brandt, Carlijn M. A. Kruitbosch, Antoinette MaassenVanDenBrink, Rolf Fronczek and Gisela M. Terwindt
    Citation: The Journal of Headache and Pain 2021 22:125

    The Correction to this article has been published in The Journal of Headache and Pain 2021 22:135

  37. Migraine has been associated with cardiovascular disease (CVD) events among middle-aged adults. The objective of this study was to determine the risk for ischemic stroke and coronary heart disease (CHD) events...

    Authors: Emily C. McKinley, Christine L. Lay, Robert S. Rosenson, Ligong Chen, Victoria Chia, Lisandro D. Colantonio, Paul Muntner, Robert Urman and Michael E. Farkouh
    Citation: The Journal of Headache and Pain 2021 22:124
  38. Obesity confers adverse effects to every system in the body including the central nervous system. Obesity is associated with both migraine and idiopathic intracranial hypertension (IIH). The mechanisms underly...

    Authors: Connar Stanley James Westgate, Ida Marchen Egerod Israelsen, Rigmor Højland Jensen and Sajedeh Eftekhari
    Citation: The Journal of Headache and Pain 2021 22:123
  39. Brain arteriovenous malformations (AVMs) consist of abnormal connections between arteries and veins via an interposing nidus. While hemorrhage is the most common presentation, unruptured AVMs can present with ...

    Authors: Benjamin N Africk, Daniel M Heiferman, Amy W Wozniak, Faraz Behzadi, Matthew S Ballard, Joshua M Chazaro, Brandon M Zsigray, Rachyl M Shanker, Matthew R Reynolds, Douglas E Anderson and Joseph C Serrone
    Citation: The Journal of Headache and Pain 2021 22:122
  40. Calcitonin gene-related peptide (CGRP) is expressed throughout the body and is a known mediator of migraine, exerting this biological effect through activation of trigeminovascular, meningeal and associated ne...

    Authors: Jason C. Ray, Penelope Allen, Ann Bacsi, Julian J. Bosco, Luke Chen, Michael Eller, Hock Kua, Lyndell L. Lim, Manjit S. Matharu, Mastura Monif, Martin Ruttledge, Richard J. Stark and Elspeth J. Hutton
    Citation: The Journal of Headache and Pain 2021 22:121
  41. In daily practice, anti-CGRP monoclonal antibodies (MAbs) may be useful in chronic migraine (CM) with medication overuse (MO), but data is limited. We evaluated their effectiveness in a real-life clinical cohort.

    Authors: Edoardo Caronna, Victor José Gallardo, Alicia Alpuente, Marta Torres-Ferrus and Patricia Pozo-Rosich
    Citation: The Journal of Headache and Pain 2021 22:120
  42. Migraine is a common neurological disease with extremely debilitating, but fully reversible symptoms. Women suffer from migraine more often than men. It was assumed that fluctuation of oestrogen level during m...

    Authors: Magdalena Kobus, Aneta Sitek, Bogusław Antoszewski, Jacek Rożniecki, Jacek Pełka and Elżbieta Żądzińska
    Citation: The Journal of Headache and Pain 2021 22:119
  43. Headache is the predominant disabler in idiopathic intracranial hypertension (IIH). The aim was to characterise headache and investigate the association with intracranial pressure.

    Authors: S. P. Mollan, B. R. Wakerley, Z. Alimajstorovic, J. Mitchell, R. Ottridge, A. Yiangou, M. Thaller, A. Gupta, O. Grech, G. Lavery, K. Brock and A. J. Sinclair
    Citation: The Journal of Headache and Pain 2021 22:118
  44. Recent data suggest that gene expression profiles of peripheral white blood cells can reflect changes in the brain. We aimed to analyze the transcriptome of peripheral blood mononuclear cells (PBMC) and change...

    Authors: Timea Aczél, Tamás Körtési, József Kun, Péter Urbán, Witold Bauer, Róbert Herczeg, Róbert Farkas, Krisztián Kovács, Barna Vásárhelyi, Gellért B. Karvaly, Attila Gyenesei, Bernadett Tuka, János Tajti, László Vécsei, Kata Bölcskei and Zsuzsanna Helyes
    Citation: The Journal of Headache and Pain 2021 22:117
  45. Authors: Lotte Skytte Krøll, Henriette Edemann Callesen, Louise Ninett Carlsen, Kirsten Birkefoss, Dagmar Beier, Henrik Wulff Christensen, Mette Jensen, Hanna Tómasdóttir, Hanne Würtzen, Christel Vesth Høst and Jakob Møller Hansen
    Citation: The Journal of Headache and Pain 2021 22:116

    The original article was published in The Journal of Headache and Pain 2021 22:96

  46. Authors: Anne-Sophie Wattiez, Olivia J. Gaul, Adisa Kuburas, Erik Zorrilla, Jayme S. Waite, Bianca N. Mason, William C. Castonguay, Mengya Wang, Bennett R. Robertson and Andrew F. Russo
    Citation: The Journal of Headache and Pain 2021 22:115

    The original article was published in The Journal of Headache and Pain 2021 22:62

  47. Monoclonal antibodies (mABs) targeting the calcitonin gene-related peptide (CGRP) pathway represent the first disease-specific preventive migraine therapy. Growing evidence suggests that they are effective in ...

    Authors: Sara Bottiroli, Roberto De Icco, Gloria Vaghi, Stefania Pazzi, Elena Guaschino, Marta Allena, Natascia Ghiotto, Daniele Martinelli, Cristina Tassorelli and Grazia Sances
    Citation: The Journal of Headache and Pain 2021 22:114

    The Correction to this article has been published in The Journal of Headache and Pain 2021 22:131